World AIDS Day this year falls at the close of an unprecedented year for the planet. The spread of COVID-19 has affected communities across the world – disrupting and threatening lives and livelihoods.
As research focused on the HIV treatment care cascade has illuminated, significant challenges remain in supporting all people living with HIV in reaching and maintaining an undetectable HIV status, thwarting both the individual and population-level benefits of this state of viral suppression
Unique barriers and facilitators to HIV testing and PrEP uptake and adherence have been reported among transgender people. HIV testing rates among transgender people are inadequate given their risk for HIV, suggesting that culturally tailored programs are needed.
The European Medicines Agency (EMA) announced today that its human medicines committee (CHMP) provided a positive benefit-risk opinion on the use of the Dapivirine Vaginal Ring (DPV-VR) for HIV prevention.
PrEP administered as an injection every eight weeks was more effective in preventing HIV than oral PrEP in gay and bisexual men and transgender women, researchers confirmed at the 23rd International AIDS Conference (AIDS 2020: Virtual) today.
